

CMCR Symposium Cannabis, Cannabinoids and Aging
October 17-18, 2024
San Diego, California

The 2024 CMCR Symposium will showcase the state of the science of the potential therapeutic effects of cannabis and cannabinoids in healthy aging and dementia and in cancer disease processes and treatment, overlapping areas in many respects. The format of the CMCR Symposium blends talks by context experts with live discussion and Q&A to explore what is known and not known, evaluate conflicting findings, and provide a roadmap for future research. We will also use this opportunity to contextualize findings from public health reports of growing use of cannabis and cannabinoids among older adults.

Our specific goals for the 2024 CMCR Symposium are threefold: to advance our understanding of the biological mechanisms of action of cannabinoids and relate that to their potential role as therapeutics in conditions that affect healthy aging, to evaluate research methods and share tools and strategies to conduct rigorous clinical and translational studies of cannabinoids, and to provide a research training experience for trainees, early-stage investigators, and established researchers who interested in cannabis research.

Target Audience

Specialties - ALL

Professions - Advanced Practice Nurse, Fellow/Resident, Medical Student, Nurse, Nurse Assistant, Other, Physician, Psychologist, Scientist / Researcher

At the completion of the conference, participants should be able to:

- Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in conditions affecting healthy aging
- Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in the treatment of dementia.
- Evaluate the biological mechanisms by which cannabinoids and the endocannabinoid system function, and assess their potential impact on cancer biology.
- Critically assess research methods and apply tools and strategies to conduct rigorous clinical and translational studies on cannabinoids.
- Assess the use of cannabinoids in clinical populations and analyze their impact on public health and safety.
- Review and discuss research priorities in cannabinoid science.
- Facilitate a comprehensive research training experience for trainees, early-stage investigators, and established researchers interested in cannabis research.
- Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in the treatment of dementia.

Program Schedule/Agenda (All times are Pacific Time)

Day 1: Thursday, October 17, 2024

8:00-8:05 **Welcome from the CMCR Director**
Igor Grant, MD
Professor of Psychiatry, UCSD
CMCR Director

2024 CMCR Symposium Awards

8:05-8:40 **Alexandros Makriyannis, PhD**

Behrakis Chair of Pharmaceutical Biotechnology and University Distinguished Professor, Northeastern University

**2024 CMCR Pioneer in Medicinal Cannabis Research Award
Presentation of Award and Keynote Address entitled "The History of Cannabis and Cannabinoids"**

The award honors leaders in cannabis and cannabinoid research conducting groundbreaking basic and translational research of cannabinoids, other constituents of cannabis, and the endocannabinoid system.

8:40-9:15

Mark A. Ware, MD, MRCP, MSc, ICDD

Alan Edwards Chair in Clinical Pain and Associate Professor of Family Medicine, McGill University

2024 CMCR Award for Advancing Cannabis and Cannabinoids as Therapeutics

Presentation of Award and Keynote Address, entitled "Cannabis and chronic pain: reflections from a 25 year journey"

The award honors those whose work has led to significant advances in our knowledge of or an expansion to the therapeutic use of cannabis and cannabinoid-based medicines.

9:15-9:55

Moderated panel discussion and Q&A

Moderator: **Igor Grant, MD**

Panelists:

Daniele Piomelli and Donald Abrams [2022]

Marilyn Huestis and Margaret Haney [2023]

9:55-10:00

5-minute break

CMCR Special Lectures

10:00-10:20

Nathaniel Schuster, MD

Associate Professor of Anesthesiology, UC San Diego School of Medicine
A randomized clinical trial of cannabis for migraine headaches

10:20-10:30

Q&A with Dr. Mark Wallace (Dr. Schuster's collaborator)

Professor of Anesthesiology, UC San Diego School of Medicine

Moderator: J. Hampton Atkinson, MD

Professor of Psychiatry, UCSD and CMCR Co-Director

10:30-10:50

Veena Ranganath, MD, MS

Clinical Professor of Medicine, UCLA School of Medicine

A randomized clinical trial of cannabidiol to reduce joint inflammation in rheumatoid arthritis

10:50-10:55

Q&A with Dr. Ranganath

Moderator: J. Hampton Atkinson, MD

10:55-11:00

5-minute break

Healthy aging

11:00-11:15

Alison Moore, MD, MPH, FACP

Professor of Medicine and Larry L. Hillblom Chair in Geriatric Medicine, University of California San Diego School of Medicine

A perspective on cannabis and aging

- 11:15-11:30** **Kim Finley, PhD**
Associate Research Professor, Shiley Bioscience Center, San Diego State University
Impact of cannabinoids on Drosophila longevity and traumatic injury response
- 11:30-11:45** **Michael Petrascheck, PhD**
Professor of Molecular and Cellular Biology, Scripps Research Institute
A lipid pathway that regulates C. elegans lifespan
- 11:45-11:55** **Moderated panel discussion with the speakers and Q&A**
Arpi Minassian, PhD (Moderator)
Professor of Psychiatry, University of California San Diego
- 11:55-12:00** **Introduction to the poster session**
Igor Grant, MD
David Grelotti, MD
Medical Director, CMCR
Scientific Chair, 2024 CMCR Symposium
- 12:00-1:00** **2024 Poster Session (Not for Credit)**

Day 2: Friday, October 18, 2024

Dementia

- 8:00-8:15** **Pamela Maher, PhD**
Research Professor, Cellular Neurobiological Laboratory, Salk Institute for Biological Studies
Cannabidiol as a potential therapeutic for the treatment of age-related neurodegenerative diseases
- 8:15-8:30** **Krista L. Lanctôt, PhD**
Professor of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto
Randomized clinical trial of nabilone for the treatment of agitation in dementia
- 8:30-8:45** **Brent Forester, MD, MSc**
Dr. Frances S. Arkin Chair of Psychiatry, Tufts University School of Medicine
Randomized clinical trial of dronabinol for the treatment of agitation in dementia
- 8:45-8:55** **Moderated panel discussion with the speakers and Q&A**
Ellen Lee, MD (Moderator)
Associate Professor and Division Chief of Geriatric Psychiatry, University of California San Diego

8:55-9:00 **5-minute break**

Cancer treatment

- 9:00-9:15** **Nephi Stella, PhD**
Professor of Pharmacology, University of Washington Medical School
Anti-tumor activity of cannabinoid-based molecules
- 9:15-9:30** **Chris Twelves, MD**
Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds School of Medicine
Nabiximols with temozolomide in patients with recurrent glioblastoma

9:30-9:45 **Joseph A. Califano, MD**
Professor of Surgery, UCSD School of Medicine
Diverse effects of cannabinoids on head and neck squamous cell carcinoma

9:45-9:55 **Moderated panel discussion with the speakers and Q&A**
Nicholas Butowski, MD (Moderator)
Professor of Neurological Surgery University of California San Francisco,
Director of Translational Research UCSF Neuro-Oncology, Medical Director of
Clinical Research Support Office at UCSF Helen Diller Family Comprehensive
Cancer Center

9:55-10:00 **5-minute break**

Use of cannabis and cannabinoids among older adults and people with cancer

10:00-10:15 **Ilana Braun, MD**
Chief of Psychosocial Oncology, Dana-Farber Cancer Institute and Assistant
Professor of Psychiatry, Harvard Medical School
Cannabis and cannabinoids in adults with cancer: ASCO Guideline

10:15-10:30 **Patricia Di Ciano, PhD**
Assistant Professor of Pharmacology and Toxicology, University of Toronto
Cannabis and driving in older adults

10:30-10:45 **Linda Hill, MD, MPH**
Distinguished Professor of Preventive Medicine and Assistant Dean, Herbert
Wertheim School of Public Health, UCSD
Impact of recreational cannabis use legalization on older adults in California

10:45-10:55 **Moderated panel discussion with the speakers and Q&A**
Thomas Marcotte, PhD (Moderator)
Professor of Psychiatry and Co-Director of CMCR, University of California San
Diego

10:55-11:00 **5-minute break**

NIH Institute Panel

11:00-11:55 **Moderated panel discussion and Q&A**
Moderator: **Steve Gust, PhD**
Chair, CMCR National Advisory Committee
Panelists: *The invited slate of stakeholders will discuss future directions
in funding for medicinal cannabis research and new directions
in aging and cancer care.*

David Shurtleff, PhD
Deputy Director
National Center for Complementary and Integrative Health

Andrew Freedman, PhD
Chief, Epidemiology and Genomics Research Program, Clinical and
Translational Epidemiology Branch
National Cancer Institute

Alexis Bakos, PhD, MPH, RN
Program Director, Division of Geriatrics and Clinical Gerontology
National Institute on Aging

Susan Weiss, PhD
Director, Division of Extramural Research
National Institute on Drug Abuse

**11:55-12:00: Closing Remarks from the CMCR Director
Igor Grant, MD**

Planning Committee

David Grelotti, MD
Associate Professor
University of California, San Diego
San Diego, CA

Carla Ingle
Project Coordinator
University of California, San Diego
San Diego, CA

Felicia Roston
Executive Assistant
University of California, San Diego
San Diego, CA

UC San Diego Faculty

J H Atkinson, MD
Professor-in-Residence Emeritus
University of California, San Diego
SAN DIEGO, CA

Joseph Califano, MD
Professor, Department of Otolaryngology-
Head and Neck Surgery
University of California, San Diego
La Jolla, CA

Igor Grant, MD, FRCP(C)
University of California, San Diego
La Jolla, CA

Linda Hill, MD, MPH
Associate Dean and Distinguished
Professor
University of California, San Diego
La Jolla, CA

Ellen E. Lee, MD
University of California, San Diego
La Jolla, CA

Visiting Faculty

Donald Abrams, MD
Professor of Clinical Medicine
UCSF
San Francisco, CA

Alexis Bakos, PhD
NIH

Ilana Braun, MD
Associate Professor
Harvard Medical School

Thomas Marcotte, PhD
Professor
University of California, San Diego
San Diego, CA

Arpi Minassian, PhD
Clinical Professor of Psychiatry
University of California, San Diego
San Diego, CA

Alison A Moore, MD, MPH
Professor
University of California, San Diego
San Diego, CA

Nathaniel Schuster, MD
University of California, San Diego

Mark S Wallace, MD
Professor of Anesthesiology
University of California San Diego Health
La Jolla, CA

Boston, MA

Nicholas Butowski, MD
Professor, Dept of Neurological Surgery
UCSF
San Francisco, CA

Patricia Di Ciano, PhD
Centre for Addiction and Mental Health
Toronto, Canada, Canada

Kim D Finley, PhD, GSA
 Research Professor
 San Diego State University
 San Diego, CA

Michael Petrascheck, PhD, Professor
 Professor
 Scripps Research
 Encinitas, CA

Brent Forester, MD
 Tufts University School of Medicine
 Boston, MA

Daniele Piomelli, PhD
 UC Irvine

Andrew Freedman, PhD
 NIH

Veena Ranganath, MD
 Clinical Professor
 University of California, Los Angeles
 Los Angeles, CA

Steven Gust, PhD

David Shurtleff, PhD
 Deputy Director NCCIH/NIH
 NIH
 Bethesda, MD

Margaret Haney, PhD
 Professor of Neurobiology (in Psychiatry)
 Columbia University
 New York, NY

Nephi Stella, PhD
 University of Washington

Marilyn Huestis, PhD
 Thomas Jefferson University

Chris Twelves, MD
 Professor
 University of Leeds
 Leeds, United Kingdom

Krista Lanctot, PhD
 Sunnybrook Res. Inst.
 Toronto, ON

Pamela Maher, PhD
 Salk Institute for Biological Studies
 La Jolla, CA

Mark Ware, MBBS
 Associate professor
 McGill University
 Montréal, Canada

Alexandros Makriyannis, PhD
 Professor
 Northeastern University
 Boston, MA

Susan RB Weiss, PhD
 National Institute on Drug Abuse
 Bethesda, MD

Disclosure Summary

It is the policy of University of California San Diego School of Medicine Continuing Professional Development to ensure that the content of accredited continuing education and related materials is accurate, balanced, objective, and scientifically justified. Education must be free of the influence or control of ineligible companies, and protect learners from promotion, marketing, and commercial bias. All persons in a position to control the content of accredited continuing education must disclose all financial relationships held with ineligible companies, prior to assuming a role in the activity. Those relationships deemed relevant to the education are mitigated prior to the activity through one of the following strategies, depending on the nature of relationship and the role of the person: 1) divesting the financial relationship, 2) altering the individual's control over content, and/or 3) validating the planning decisions and/or content through independent peer review. All relevant financial relationships are mitigated prior to the activity and mitigation strategies and necessary steps for implementation are communicated to individuals prior to them assuming their role in the activity. Persons who refuse or fail to disclose are disqualified from participating in the activity. Activities are evaluated by participants and peer reviewers to determine if the content was free of bias and met acceptable scientific standards. This information is considered in future activity planning. ***All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.***

Faculty Member Name	Role in Activity	Name of Ineligible Company(ies)/Nature of Relationship(s)
Donald Abrams, MD	Faculty	Advisor-Cannformatics Advisor-Cannabotech Advisor-Wellkasa Advisor-Lumen - 06/26/2024
Daniele Piomelli, PhD	Faculty	Advisor-Exxel Pharma Stocks or stock options, excluding diversified mutual funds-Exxel Pharma - 04/17/2024

Nicholas Butowski, MD	Faculty	Advisor-Plus Therapeutics Advisor-Bayer (Any division) Advisor-Ino8 Bio Advisor-Ipsen Biopharmaceuticals, Inc. Advisor-Novartis Corporation Pharmaceuticals Advisor-Sapience Advisor-Sapience Membership on Advisory Committees or Review Panels, Board Membership, etc.- VBI Membership on Advisory Committees or Review Panels, Board Membership, etc.-Plus Therapeutics - 10/14/2024
Krista Lanctot, PhD	Faculty	Consulting Fee-Cerevel Consulting Fee-ICG Pharma - 05/29/2024
Brent Forester, MD	Faculty	Consulting Fee-CVS Membership on Advisory Committees or Review Panels, Board Membership, etc.-CVS Advisor-Patina Health Advisor-Rippl Care - 08/19/2024
Nathaniel Schuster, MD	Faculty	Consulting Fee-Eli Lilly & Co. Consulting Fee-Averitas Consulting Fee-ShiraTronics Consulting Fee-Schedule 1 Therapeutics Advisor-Vectura Fertin Advisor-Rapport Advisor-Lohocla Grant or research support-National Football League Grant or research support-Novaremed Stocks or stock options, excluding diversified mutual funds-Altamont - 09/27/2024
Nephi Stella, PhD	Faculty	Consulting Fee-Stella Consulting, LLC - 08/05/2024
MARK WALLACE, MD	Faculty	Consulting Fee-TerraSera - 06/26/2024
Veena Ranganath, MD	Faculty	Grant or research support-Mallinckrodt Pharmaceuticals - 09/13/2024
Margaret Haney, PhD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pleo Pharma - 06/27/2024
Chris Twelves, MD	Faculty	Speakers Bureau-Novartis Corporation Pharmaceuticals Speakers Bureau-Pfizer (Any division) - 07/11/2024
Susan Weiss, PhD	Faculty	Stocks or stock options, excluding diversified mutual funds-Merck (Any division) - 07/18/2024

Persons in control of content of this educational activity who are not specifically identified by name above, such as (but not limited to) course directors, faculty, CME staff, planners, editorial staff, peer reviewers, and CME committee reviewers do not have any relevant financial relationships.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California San Diego School of Medicine.

Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this live activity for a maximum of **7.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Anesthesiology (ABA): This activity contributes to the CME component of the American Board of Anesthesiology's redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

American Board of Pathology (ABPath): The activity has been registered to offer credit in the American Board of Pathology's Continuing Certification program on activity materials. This Lifelong Learning (CME) activity enables the participant to earn up to **7.25**.

American Board of Surgery (ABS): Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Thoracic Surgery (ABTS): Successful completion of this CME activity enables the learner to earn credit toward the CME of the American Board of Thoracic Surgery's Maintenance of Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.

Cultural & Linguistic Competency and Implicit Bias:

Continuing medical education (CME) providers are required by state Assembly Bills 1195 and 241, and the standards created by the California Medical Association (CMA), to include components that address cultural and linguistic competency and implicit bias in CME activities. The planners and presenters of this activity has been asked to provide meaningful consideration of these standards in the selection and presentation of content. Additional information and resources are available on the UC San Diego CME website (cpd.ucsd.edu)

Commercial Support Acknowledgement

We would like to thank the following companies for providing educational support of this activity:

Direct Support:

Jazz Pharmaceuticals, Inc.